Valuation: Cadrenal Therapeutics, Inc.

Market Cap 3.37M 3.01M 2.78M 2.52M 4.71M 321M 4.78M 33.18M 13.24M 168M 12.63M 12.36M 531M P/E 2026 *
-0.24x
P/E 2027 * -0.31x
Enterprise Value 3.37M 3.01M 2.78M 2.52M 4.71M 321M 4.78M 33.18M 13.24M 168M 12.63M 12.36M 531M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
90.34%
Yield 2026 *
-
Yield 2027 * -
10-07 Cadrenal Therapeutics, Inc. Initiates Formal Strategic Process to Evaluate Opportunities to Maximize the Value of the Company and Its Asset Portfolio CI
10-07 Cadrenal Therapeutics Initiates Formal Strategic Process to Evaluate Opportunities Involving Cad-1005, Tecarfarin, Frunexian and Cad-2000 CI
08-31 Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of Cad-1005 in Heparin-Induced Thrombocytopenia CI
08-13 Cadrenal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-03 Cadrenal Therapeutics Solidifies Multi-Indication Strategy For CAD-1005 In Cardiac Acute Critical Care CI
07-13 Cadrenal Therapeutics, Inc. Demonstrates Greater Than 25% Reduction in Thrombotic Events with CAD-1005 in Phase 2 Hit Clinical Trial CI
07-10 Cadrenal Therapeutics, Inc. Announces Resignation of James J. Ferguson III from Chief Medical Officer Role, Effective July 31, 2026 CI
07-01 Cadrenal Therapeutics Prices Private Placement for Up to $8.8 Million MT
06-29 Cadrenal Therapeutics, Inc. announced that it expects to receive $3 million in funding CI
06-29 Cadrenal Therapeutics, Inc. Announces CFO Changes CI
06-29 Cadrenal Therapeutics, Inc. Announces Board and Committee Changes CI
06-24 Cadrenal Therapeutics Announces Selection of Cad-1005 Phase 2 Study for Late-Breaking Oral Presentation At Isth Congress CI
06-18 Cadrenal Therapeutics, Inc. Plans To Submit Rare Pediatric Disease Designation Request For Tecarfarin In Kawasaki Disease CI
1 day-0.47%
1 week-2.74%
Current month-12.65%
1 month-13.45%
3 months-52.11%
6 months-83.12%
Current year-86.09%
1 week 0.86
Extreme 0.86
1
1 month 0.82
Extreme 0.8163
1.12
Current year 0.82
Extreme 0.8163
8.96
1 year 0.82
Extreme 0.8163
13.75
3 years 0.82
Extreme 0.8163
32.55
5 years 0.82
Extreme 0.8163
101.25
10 years 0.82
Extreme 0.8163
101.25
Manager TitleAgeSince
Chief Executive Officer 61 24/01/2022
Director of Finance/CFO 61 24/06/2026
Chief Operating Officer 58 05/02/2024
Director TitleAgeSince
Director/Board Member 76 18/01/2023
Director/Board Member 78 18/01/2023
Chairman 61 24/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
09/10/26 Free

Director

75,000 2.1023%
09/10/26 Free

Chief Operating Officer

150,000 4.2045%
09/10/26 Free

Director

75,000 2.1023%
Change 5-day change 1-year change 3-year change Capi.($)
-0.47%-2.74%-92.66%-86.55% 3.37M
+0.34%+1.12%+34.75%+61.06% 64.38B
-0.32%+2.53%+14.18%+83.36% 56.16B
+0.92%+2.41%+15.87%+107.70% 54.16B
-1.43%-1.17%+26.27%+52.86% 45.33B
-0.48%-2.80%+18.01%+117.99% 42.25B
+0.82%+1.37%+227.94%+922.41% 40.78B
+0.30%+43.72%+106.58%+90.86% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average -0.18%+3.78%+38.51%+138.29% 39.27B
Weighted average by Cap. -0.06%+3.60%+50.06%+162.20%

Financials

2026 *2027 *
Net sales - -
Net income -12.6M -11.29M -10.41M -9.42M -17.62M -1.2B -17.9M -124M -49.56M -628M -47.29M -46.28M -1.99B -17.2M -15.41M -14.21M -12.86M -24.05M -1.64B -24.44M -170M -67.65M -857M -64.55M -63.18M -2.71B
Net Debt - -
Projected Income Statement - Annual - Cadrenal Therapeutics, Inc.
Logo Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.
Employees
-
Date Price Change Volume
29/10/26 US$0.9434 -0.47% 44,039
28/10/26 US$0.9479 +0.59% 37,454
27/10/26 US$0.9423 +3.55% 60,404
26/10/26 US$0.9100 -5.21% 52,213
23/10/26 US$0.9600 -1.03% 38,236
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cadrenal Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.9434USD
Average target price
14.00USD
Spread / Average Target
+1,383.99%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cadrenal Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CVKD Stock